Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An inherited disorder affecting the metabolism of bilirubin. It results in increased levels of bilirubin in the blood. Representative examples of this condition include Gilbert syndrome and Crigler-Najjar syndrome.
No HPO annotations are available for this condition.
The only clinical feature of Rotor syndrome is mild jaundice due to conjugated and unconjugated hyperbilirubinemia that usually begins shortly after birth or in childhood. Jaundice may be intermittent. Conjunctival icterus may be the only clinical manifestation.
Source: GeneReviews — "Rotor Syndrome"
Suggestive Findings Rotor syndrome should be suspected in individuals with the following clinical, laboratory, and cholescintigraphy findings and family history. Clinical findings • Mild jaundice (may be intermittent) • Conjunctival icterus (in some affected individuals) • Otherwise normal physical examination Laboratory findings (See .) • Conjugated hyperbilirubinemia with serum total bilirubin concentration usually between 2 and 5 mg/dL but possibly higher. Conjugated bilirubin usually exceeds 50% of total bilirubin. • Presence of bilirubin in the urine • Absence of hemolysis* • Normal serum alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and gamma-glutamyl transferase (GGT) activity* • Total urinary porphyrins: elevated coproporphyrin *Tests for hemolysis and measurements of ALT, AST, ALP, and GGT activity are needed to evaluate for hemolytic anemia and hepatobiliary diseases that are considered in the of Rotor syndrome. Cholescintigraphy findings. Radiotracers (99mTc-HIDA/99mTc-N [2,6-dimethylphenyl-carbamoylmethyl] iminodiacetic acid, 99mTc-DISIDA/disofenin, 99mTc-BrIDA/mebrofenin) are taken up slowly by the liver and the liver is scarcely visualized; however, the cardiac blood pool is persistently visualized, with prominent excretion by the kidneys. Family history is consistent with autosomal recessive inheritance (e.g., affected sibs and/or parental consanguinity). Absence of a known family history does not preclude the diagnosis. Table 1. Laboratory Findings in Rotor Syndrome
No approved treatments are currently available for hereditary hyperbilirubinemia. The disease remains an area of unmet medical need.
No clinical practice guidelines for Rotor syndrome have been published as no treatment or surveillance is recommended.
In most instances an individual diagnosed with Rotor syndrome is the child of a consanguineous couple. In some centers, identification of consanguinity may be an indication for consultation with a clinical geneticist, certified genetic counselor, certified genetic nurse, or genetics advanced practice provider (nurse practitioner or physician assistant).
No clinical trials have been registered for hereditary hyperbilirubinemia.
278 publications have been identified in PubMed for hereditary hyperbilirubinemia. Kisho has analyzed 149 by research type. Research spans Epidemiology / Natural History (30%), Review / Meta-Analysis (26%), and Basic Science / Preclinical (15%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 45 | 30% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 11:53 AM UTC
Laboratory Finding | Rotor Syndrome | Normal |
|---|---|---|
Total bilirubin | 2-5 mg/dL1 | 0.3-1.0 mg/dL2 |
Conjugated:total bilirubin ratio | 50% | 20% |
Liver enzymes | Normal | Normal |
Hemolysis | None | None Urine |
Bilirubin | Present | Not detected |
Coproporphyrins | 2.5-5x normal3 | 1. Rarely, levels exceeding 20 mg/dL are possible . For total and direct bilirubin in persons older than age one year. Note: Although normal levels of total and direct bilirubin may be higher in the neonatal period and infancy, Rotor syndrome is not usually diagnosed in this age group. |
Source: GeneReviews — "Rotor Syndrome"
Inherited disorders of bilirubin clearance can present with either conjugated or unconjugated hyperbilirubinemia. Dubin-Johnson syndrome, a benign conjugated hyperbilirubinemia similar to Rotor syndrome, is caused by decreased secretion of conjugated bilirubin into bile. Defects in bilirubin conjugation resulting in increased levels of unconjugated bilirubin are represented by Gilbert syndrome, Crigler-Najjar syndrome type II, and Crigler-Najjar syndrome type I (a rare, severe, life-threatening disease associated with kernicterus typically manifesting within the first days after birth). Since Rotor syndrome is usually diagnosed after the neonatal period, only benign forms of genetic jaundice are included in the differential diagnosis .
Table 3.
Source: GeneReviews — "Rotor Syndrome"
Biomarker and diagnostic research for hereditary hyperbilirubinemia has been reported in the published literature.
No treatment is required.
No adverse drug effects have been documented in Rotor syndrome; however, the absence of the hepatic proteins SLCO1B1 and SLCO1B3 may have serious consequences for liver uptake and toxicity of numerous commonly used drugs and/or their metabolites, which enter the liver via either of the two OATP1B transporters. A list of drugs that enter the liver mainly via SLCO1B1 and whose pharmacokinetics are known to be influenced by genetic variability in SLCO1B1 or inhibition of SLCO1B1/3 has been published . Some of these drugs are also taken up by SLCO1B3 .
Source: GeneReviews — "Rotor Syndrome"
No adverse drug effects have been documented in Rotor syndrome; however, the absence of the hepatic proteins SLCO1B1 and SLCO1B3 may have serious consequences for liver uptake and toxicity of numerous commonly used drugs and/or their metabolites, which enter the liver via either of the two OATP1B transporters. A list of drugs that enter the liver mainly via SLCO1B1 and whose pharmacokinetics are known to be influenced by genetic variability in SLCO1B1 or inhibition of SLCO1B1/3 has been published . Some of these drugs are also taken up by SLCO1B3 .
Statins – simvastatin, atorvastatin, pravastatin, pitavastatin, rosuvastatin
Ezetimibe
Anticancer drugs – methotrexate and irinotecan, cabazitaxel, some tyrosine kinase inhibitors (e.g., sunitinib)
Sartans – olmesartan and valsartan
Rifampicin
Mycophenolic acid
Torsemide
Thiazolidine diones – pioglitazone and rosiglitazone
Glinides – nateglinide and repaglinide
Lopinavir
Fexofenadine
Cyclosporin A
Source: GeneReviews — "Rotor Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Rotor Syndrome"
View trials for hereditary hyperbilirubinemia
Research summaries |
38 |
26% |
Laboratory research | 23 | 15% |
Testing and diagnosis research | 15 | 10% |
Patient case studies | 14 | 9% |
Clinical study results | 13 | 9% |
Other research | 1 | 1% |
Huang D (2026). [PMID: 40939888](https://pubmed.ncbi.nlm.nih.gov/40939888/). *J Genet Genomics*. [Basic Science / Preclinical]
Jayanti S (2026). [PMID: 41861098](https://pubmed.ncbi.nlm.nih.gov/41861098/). *Adv Sci (Weinh)*. [Review / Meta-Analysis]
Grant LM (2026). [PMID: 29262099](https://pubmed.ncbi.nlm.nih.gov/29262099/). *Unknown Journal*. [Review / Meta-Analysis]
Sayin AZ (2026). [PMID: 41543361](https://pubmed.ncbi.nlm.nih.gov/41543361/). *CPT Pharmacometrics Syst Pharmacol*. [Epidemiology / Natural History]
Dangedara M (2026). [PMID: 42243717](https://pubmed.ncbi.nlm.nih.gov/42243717/). *BMC Infect Dis*. [Case Report / Case Series]
Kwo PY (2026). [PMID: 41831501](https://pubmed.ncbi.nlm.nih.gov/41831501/). *Gastroenterology*. [Review / Meta-Analysis]
Chung BK (2026). [PMID: 40560681](https://pubmed.ncbi.nlm.nih.gov/40560681/). *Hepatology*. [Basic Science / Preclinical]
Lai NM (2026). [PMID: 41784088](https://pubmed.ncbi.nlm.nih.gov/41784088/). *Cochrane Database Syst Rev*. [Review / Meta-Analysis]
Bajaj JS (2026). [PMID: 40618943](https://pubmed.ncbi.nlm.nih.gov/40618943/). *Clin Gastroenterol Hepatol*. [Epidemiology / Natural History]
Adenawoola MI (2026). [PMID: 42193976](https://pubmed.ncbi.nlm.nih.gov/42193976/). *Biomolecules*. [Review / Meta-Analysis]